drugset
drugset / Trial / NCT05847439

A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male Participants

NCT05847439 ↗

Phase 1 Completed 8 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (PK), metabolite profile, routes and extent of elimination, mass balance, as well as safety and tolerability of \[14C\]BMS-986419 in healthy male participants.

Timeline

Start
2023-05-05
Primary completion
2023-07-05
Completion
2023-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986419 Unknown — —

Indications

No indication recorded.